Form 4: Amgen SVP & CCO Nancy A. Grygiel Reports Changes in Beneficial Ownership

Nancy A. Grygiel, SVP & CCO of Amgen Inc., reports a disposition of shares to cover tax obligations related to vested Restricted Stock Units (RSUs) and updates holdings in the company's 401(k) plan.

Summary

• On March 18, 2024, Nancy A. Grygiel, SVP & CCO of Amgen Inc., reported a transaction involving Amgen's common stock.
• The transaction involved the disposition of 703 shares at a price of $268.87 per share to cover tax obligations.
• Following the transaction, Grygiel directly owns 12,220 shares of Amgen common stock.
• Grygiel also indirectly owns 99.9653 shares through the company's 401(k) plan.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, reflecting neutral sentiment. It reports transactions related to executive compensation, which are routine.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies like Amgen.

Comparison to Industry Standards

• Form 4 filings are standard practice for executives at publicly traded companies, ensuring transparency in their stock transactions.
• Executive compensation packages, including RSUs, are common across the pharmaceutical industry, with vesting schedules and tax implications that necessitate such filings.

Stakeholder Impact

• The filing provides transparency to shareholders regarding executive stock ownership.
• The transactions reported are part of the executive's compensation package and do not directly impact other stakeholders.

Key Dates